521 related articles for article (PubMed ID: 19567679)
1. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
2. Primary antitumor immune response mediated by CD4+ T cells.
Corthay A; Skovseth DK; Lundin KU; Røsjø E; Omholt H; Hofgaard PO; Haraldsen G; Bogen B
Immunity; 2005 Mar; 22(3):371-83. PubMed ID: 15780993
[TBL] [Abstract][Full Text] [Related]
3. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
Corthay A; Lorvik KB; Bogen B
Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
5. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF
Eur J Immunol; 1995 Nov; 25(11):3079-86. PubMed ID: 7489746
[TBL] [Abstract][Full Text] [Related]
6. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
7. Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Tveita AA; Schjesvold F; Haabeth OA; Fauskanger M; Bogen B
Cancer Res; 2015 Aug; 75(16):3268-78. PubMed ID: 26038231
[TBL] [Abstract][Full Text] [Related]
8. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
9. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity.
Eck SC; Turka LA
Cancer Res; 2001 Apr; 61(7):3077-83. PubMed ID: 11306490
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
11. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
12. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.
Lauritzsen GF; Bogen B
Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665
[TBL] [Abstract][Full Text] [Related]
13. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
Bogen B
Eur J Immunol; 1996 Nov; 26(11):2671-9. PubMed ID: 8921954
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
15. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor.
Klein L; Trautman L; Psarras S; Schnell S; Siermann A; Liblau R; von Boehmer H; Khazaie K
Eur J Immunol; 2003 Mar; 33(3):806-14. PubMed ID: 12616501
[TBL] [Abstract][Full Text] [Related]
16. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
17. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
Cuenca A; Cheng F; Wang H; Brayer J; Horna P; Gu L; Bien H; Borrello IM; Levitsky HI; Sotomayor EM
Cancer Res; 2003 Dec; 63(24):9007-15. PubMed ID: 14695219
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
19. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
20. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
